General description
A potent quinoxaline-based PARP inhibitor with a ~5-fold selectivity towards PARP-2 over PARP-1 (IC50 = 7 and 33 nM, respectively). Reported to be brain-permeant and exhibit good pharmacokinetics.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Ishida, J., et al. 2006. Bioorg. Med. Chem.14, 1378.Iwashita, A., et al. 2005. FEBS Lett.579, 1389.
Packaging
5 mg in Glass bottle
Packaged under inert gas
Warning
Toxicity: Irritant (B)
This product has met the following criteria to qualify for the following awards: